Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
July 9, 2021Targovax announces resignation of Chief Financial Officer, Torbjørn Furuseth
-
July 2, 2021Targovax ASA issues options to new member of management
-
July 1, 2021Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
-
June 28, 2021Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition
Q1 First quarter 2021
Targovax ASA announced its first quarter 2021 results on Thursday 6 May 2021. An online presentation by Targovax’s management to investors, analysts and the press took place the same day at 10:00 am CEST.